{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T16:11:48Z","timestamp":1695485508197},"reference-count":29,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.3892\/ol.2013.1178","type":"journal-article","created":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T12:34:01Z","timestamp":1360067641000},"page":"1123-1128","source":"Crossref","is-referenced-by-count":2,"title":["Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy"],"prefix":"10.3892","volume":"5","author":[{"given":"KAYOKO","family":"KIBATA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKESHI","family":"TAMAKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NORIKO","family":"INAGAKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAKOTO","family":"OGATA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOSHIKI","family":"SHIMIZU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHOSAKU","family":"NOMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,2,5]]},"reference":[{"key":"key20180108092520_b1-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155208100450","article-title":"Nail toxicity induced by cancer chemotherapy","volume":"15","author":"Gilbar","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"key20180108092520_b2-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"key20180108092520_b3-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.lungcan.2009.04.021","article-title":"Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers","volume":"67","author":"Tiseo","year":"2010","journal-title":"Lung Cancer"},{"key":"key20180108092520_b4-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000118626","article-title":"A pilot study of docetaxel and trofosfamide as second-line \u2018metronomic\u2019 chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)","volume":"31","author":"G\u00f6rn","year":"2008","journal-title":"Onkologie"},{"key":"key20180108092520_b5-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3747\/co.19.879","article-title":"Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer","volume":"19","author":"Young","year":"2012","journal-title":"Curr Oncol"},{"key":"key20180108092520_b6-ol-05-04-1123","first-page":"4317","article-title":"Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure","volume":"30","author":"Ladoire","year":"2010","journal-title":"Anticancer Res"},{"key":"key20180108092520_b7-ol-05-04-1123","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"key20180108092520_b8-ol-05-04-1123","first-page":"4342","article-title":"Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini","year":"2003","journal-title":"Cancer Res"},{"key":"key20180108092520_b9-ol-05-04-1123","first-page":"2731","article-title":"Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water","volume":"62","author":"Man","year":"2002","journal-title":"Cancer Res"},{"key":"key20180108092520_b10-ol-05-04-1123","first-page":"15","article-title":"A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer","volume":"3","author":"Yokoi","year":"2012","journal-title":"Lung Cancer: Targets and Therapy"},{"key":"key20180108092520_b11-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jjco\/hym042","article-title":"Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer","volume":"37","author":"Hong","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"key20180108092520_b12-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3349\/ymj.2007.48.1.124","article-title":"Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration","volume":"48","author":"Roh","year":"2007","journal-title":"Yonsei Med J"},{"key":"key20180108092520_b13-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000018132","article-title":"Nail changes secondary to docetaxel (Taxotere)","volume":"198","author":"Correia","year":"1999","journal-title":"Dermatology"},{"key":"key20180108092520_b14-ol-05-04-1123","first-page":"99","volume-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2002","edition":"6th edition"},{"key":"key20180108092520_b15-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key20180108092520_b16-ol-05-04-1123","unstructured":"National Cancer Institute (NCI)Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, 28 May 2009http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed October 9, 2012."},{"key":"key20180108092520_b17-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a058907","article-title":"A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group","volume":"5","author":"ten Bokkel Huinink","year":"1994","journal-title":"Ann Oncol"},{"key":"key20180108092520_b18-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2005.06862.x","article-title":"Diagnosis of nail psoriasis: importance of biopsy and histopathology","volume":"153","author":"Grover","year":"2005","journal-title":"Br J Dermatol"},{"key":"key20180108092520_b19-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jaad.2006.12.019","article-title":"Onychomycosis: diagnosis and definition of cure","volume":"56","author":"Scher","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"key20180108092520_b20-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1468-3083.2004.01068.x","article-title":"Hyperkeratotic nail discoid lupus erythematosus evolving towards systemic lupus erythematosus: therapeutic difficulties","volume":"18","author":"Richert","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20180108092520_b21-ol-05-04-1123","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.04.2011.4157","article-title":"Unilateral onycholysis in a patient taking erlotinib (Tarceva)","author":"Stevenson","year":"2011","journal-title":"BMJ Case Rep"},{"key":"key20180108092520_b22-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D31NF6W9Q1","article-title":"Unilateral taxane-induced onychopathy in a patient with a brain metastasis","volume":"15","author":"Truchuelo","year":"2009","journal-title":"Dermatol Online J"},{"key":"key20180108092520_b23-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1365-2230.1992.tb00259.x","article-title":"Unilateral subungual hyperkeratosis following a cerebrovascular incident in a patient with psoriasis","volume":"17","author":"Badger","year":"1992","journal-title":"Clin Exp Dermatol"},{"key":"key20180108092520_b24-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1016002329546","article-title":"Docetaxel-induced nail changes - a neurogenic mechanism: a case report","volume":"58","author":"Wasner","year":"2002","journal-title":"J Neurooncol"},{"key":"key20180108092520_b25-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1254\/jphs.12014FP","article-title":"Neurogenic vascular responses in male mouse mesenteric vascular beds","volume":"119","author":"Fujiwara","year":"2012","journal-title":"J Pharmacol Sci"},{"key":"key20180108092520_b26-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1476-5381.1985.tb11107.x","article-title":"Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability","volume":"86","author":"Brain","year":"1985","journal-title":"Br J Pharmacol"},{"key":"key20180108092520_b27-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s004010051132","article-title":"Docetaxel neuropathy: a distal axonopathy","volume":"98","author":"Fazio","year":"1999","journal-title":"Acta Neuropathol"},{"key":"key20180108092520_b28-ol-05-04-1123","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1212\/WNL.46.1.108","article-title":"Peripheral neuropathy secondary to docetaxel (Taxotere)","volume":"46","author":"New","year":"1996","journal-title":"Neurology"},{"key":"key20180108092520_b29-ol-05-04-1123","first-page":"4413","article-title":"Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy","volume":"31","author":"Koskinen","year":"2011","journal-title":"Anticancer Res"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2013.1178\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T14:42:08Z","timestamp":1644244928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2013.1178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,5]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,2,5]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.3892\/ol.2013.1178"],"URL":"https:\/\/doi.org\/10.3892\/ol.2013.1178","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,5]]}}}